Maintenance Therapy Cessation Effects in MRD-Negative Multiple Myeloma Remission

This study focuses on people with multiple myeloma, a type of blood cancer, who are in a state called MRD-negative remission. This means their cancer is under control and minimal residual disease (MRD) is not detectable. The main goal is to test if stopping maintenance therapy, the ongoing treatment to keep cancer in check, has the same effect on disease control as continuing it. The importance of this study lies in exploring if patients can safely stop maintenance therapy and switch to active surveillance, potentially improving their quality of life while keeping the cancer at bay. In this observational study, participants who are currently on maintenance therapy will stop this treatment and transition to active surveillance. The primary outcome measured is Progression Free Survival, which means maintaining the MRD-negative state for at least one year after enrolling in the study. This will help determine if stopping maintenance therapy is as effective as continuing it for disease control.